Post-Progression Survival Associated with Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Docetaxel Monotherapy as Second-Line Chemotherapy

Publisher： Karger

E-ISSN： 1421-9794|62|4|205-213

ISSN： 0009-3157

Source： Chemotherapy, Vol.62, Iss.4, 2017-04, pp. : 205-213

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Cost-Effectiveness Analysis of Docetaxel versus Pemetrexed in Second-Line Chemotherapy for Stage IIIb or IV Non-Small Cell Lung Cancer in China

By  

Chemotherapy, Vol. 56, Iss. 6, 2010-11 ,pp. : 472-477

Karger

Access to resources Recommend Favorite

A Method for Biomarker Directed Survival Prediction in Advanced Non-Small-Cell Lung Cancer Patients Treated with Carboplatin-Based Therapy

By Chen Wei   Bepler Gerold  

Journal of Personalized Medicine, Vol. 3, Iss. 3, 2013-09 ,pp. : 251-262

MDPI

Access to resources Recommend Favorite

Prognostic Index for Survival in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Third-Generation Agents

By  

Chemotherapy, Vol. 62, Iss. 4, 2017-05 ,pp. : 239-245

Karger

Access to resources Recommend Favorite

Factors Associated with Post-Progression Survival in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib

By Otsuka Taiga   Nakashita Shunya   Yanagita Kimihiko   Ario Keisuke   Kawasoe Hiroaki   Kawazoe Seiji   Eguchi Yuichiro   Mizuta Toshihiko   Chan Stephen L.  

Diseases, Vol. 3, Iss. 2, 2015-05 ,pp. : 68-77

MDPI

Access to resources Recommend Favorite

Gemcitabine Plus Vinorelbine as the Second-Line Treatment and Beyond in Elderly Patients with Platinum-Pretreated Advanced Non-Small Cell Lung Cancer

By  

Chemotherapy, Vol. 60, Iss. 4, 2015-04 ,pp. : 267-273

Karger

Access to resources Recommend Favorite